<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000437.pub3" GROUP_ID="NEONATAL" ID="051502021808101887" MERGED_FROM="" MODIFIED="2015-10-16 15:00:22 +0100" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.6&lt;/p&gt;&lt;p&gt;CL 1/06 (review)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-10-16 13:21:22 +1000" NOTES_MODIFIED_BY="Liz Dooley" REVIEW_NO="" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.4">
<COVER_SHEET MODIFIED="2015-10-16 13:21:22 +1000" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2015-08-27 15:54:17 +1000" MODIFIED_BY="[Empty name]">Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants</TITLE>
<CONTACT>
<PERSON ID="EEE82C9782E26AA20126CDD1B6925085" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Maria Ximena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rojas-Reyes</LAST_NAME>
<SUFFIX>RN. MSc.Ph.D</SUFFIX>
<POSITION>Clinical Epidemiologist, Associate Professor in Clinical Epidemiology</POSITION>
<EMAIL_1>mxrojas@gmail.com</EMAIL_1>
<EMAIL_2>mxrojas@javeriana.edu.co</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1>Cr. 7 #40-62, 2nd floor</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bogotá D.C.</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+57 1 320 8320 ext 2811</PHONE_1>
<PHONE_2>+57 1 320 8320 ext 2799</PHONE_2>
<FAX_1>+57 1 285 6981</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-10-16 13:21:22 +1000" MODIFIED_BY="Liz Dooley">
<PERSON ID="EEE82C9782E26AA20126CDD1B6925085" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Maria Ximena</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rojas-Reyes</LAST_NAME>
<SUFFIX>RN. MSc.Ph.D</SUFFIX>
<POSITION>Clinical Epidemiologist, Associate Professor in Clinical Epidemiology</POSITION>
<EMAIL_1>mxrojas@gmail.com</EMAIL_1>
<EMAIL_2>mxrojas@javeriana.edu.co</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1>Cr. 7 #40-62, 2nd floor</ADDRESS_1>
<ADDRESS_2/>
<CITY>Bogotá D.C.</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+57 1 320 8320 ext 2811</PHONE_1>
<PHONE_2>+57 1 320 8320 ext 2799</PHONE_2>
<FAX_1>+57 1 285 6981</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1505131807061382167960530719276" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Paola</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Orrego-Rojas</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>paolaorrego1206@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>Pontificia Universidad Javeriana</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bogotá D.C.</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-10-16 13:14:31 +1000" MODIFIED_BY="Liz Dooley">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="2" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="10" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-08-29 21:40:24 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-08-29 21:40:24 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>GRADE assessment and 'Summary of findings' table were added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-08-27 16:01:56 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="6" YEAR="2015"/>
<DESCRIPTION>
<P>Search was updated in June 2015. No new trials were identified for inclusion</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-08-27 16:02:17 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-07-23 00:54:07 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Updated June 30, 2013</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-08-27 16:02:10 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="20" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Electronic search updated in June 2013. No new studies identified for inclusion. Conclusions unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-08-27 16:02:17 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-07-21 06:08:10 +1000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Royal North Shore Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Sydney Children's Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-07-21 06:08:10 +1000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-07-21 06:08:10 +1000" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201100016C.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-10-13 03:03:08 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-08-29 23:27:40 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-08-27 16:22:21 +1000" MODIFIED_BY="[Empty name]">Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2015-08-29 23:27:40 +1000" MODIFIED_BY="[Empty name]">
<P>
<B>Background: </B>In very low birth weight infants who require support on breathing machines (ventilators), ventilator-associated lung injury and toxic effects of oxygen may be important factors in creating a chronic disturbance in lung function. Compared with routine conventional ventilators, high-frequency jet ventilators (breathing machines that introduce short-duration pulses of gas under pressure into the airway at a very fast rate) may reduce the severity of lung injury associated with mechanical ventilation.</P>
<P>
<B>Question:</B> In preterm infants with severe respiratory dysfunction despite attempts at conventional ventilator support, does use of rescue high-frequency jet ventilation compared with ongoing conventional ventilation decrease the risk of lung injury (chronic lung disease) or death?</P>
<P>
<B>Study characteristics: </B>One study randomly assigned 166 preterm infants and reported data on 144 infants. The included study was completed before the introduction of surfactant and widespread use of antenatal steroids.</P>
<P>
<B>Key Results:</B> This trial demonstrated no differences in outcomes among infants who received high-frequency jet ventilation. In this trial, cross-over to the alternate treatment was permitted if initial treatment failed. Investigators found no statistically significant differences in overall mortality (including survival after cross-over) between the two groups. In a secondary analysis, researchers showed that rescue treatment with HFJV, up to the time of cross-over, was associated with lower mortality. Researchers reported no differences in the incidence of chronic lung disease among survivors at 28 days of age, and they found no differences in intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.</P>
<P>
<B>Conclusions:</B> Existing evidence does not support the use of rescue high-frequency jet ventilation compared with conventional mechanical ventilation for treatment of preterm infants with severe pulmonary problems. Additional research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-08-29 23:23:04 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-08-27 17:36:36 +1000" MODIFIED_BY="[Empty name]">
<P>Chronic lung disease (CLD) is a major cause of mortality and morbidity in very low birth weight infants despite increased use of antenatal steroids and surfactant therapy. Ventilator injury and oxygen toxicity are thought to be important factors in the pathogenesis of chronic pulmonary disease. Evidence from animal studies and from adult human studies indicates that high-frequency jet ventilation may reduce the severity of lung injury associated with mechanical ventilation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-08-29 23:16:19 +1000" MODIFIED_BY="[Empty name]">
<P>To compare use of high-frequency jet ventilation (HFJV) versus conventional ventilation (CV) in preterm infants with severe pulmonary dysfunction.</P>
<P>Subgroup analyses include the following.</P>
<P>&#8226; Trials with and without surfactant replacement therapy.</P>
<P>&#8226; Trials with and without strategies to maintain lung volume.</P>
<P>&#8226; Trials with infants of different gestational ages and birth weights (specific subgroups to include &lt; 28 weeks' gestation and &lt; 1000 grams).</P>
<P>&#8226; Trials with and without adequate humidification of inspired gases.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-08-29 21:43:23 +1000" MODIFIED_BY="[Empty name]">
<P>The original search included MEDLINE (1966 to August 2005), the Cochrane Central Register of Controlled Trials (CENTRAL; 2005, Issue 3) and EMBASE (1988 to August 2005). We also obtained information from experts in the field and checked cross-references. We updated the electronic search in June 2013 and again in June 2015.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-08-29 22:13:50 +1000" MODIFIED_BY="[Empty name]">
<P>We included in this systematic review randomised and quasi-randomised controlled trials of rescue high-frequency jet ventilation versus conventional ventilation in preterm infants born at less than 35 weeks' gestation or with birth weight less than 2000 grams in respiratory distress.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-08-27 16:13:57 +1000" MODIFIED_BY="[Empty name]">
<P>We used standard methods of the Cochrane Neonatal Review Group, including independent trial assessment and data extraction. We analysed data using risk ratios (RRs) and risk differences (RDs).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-08-29 23:23:04 +1000" MODIFIED_BY="[Empty name]">
<P>We included only one trial in the review. <A HREF="Keszler 1991">Keszler 1991</A> randomly assigned 166 preterm infants; reported data on 144 infants; and permitted cross-over to the alternate treatment if initial treatment failed. Investigators found no statistically significant differences in overall mortality (including survival after cross-over) between the two groups (RR 1.07, 95% confidence interval (CI) 0.67 to 1.72). In a secondary analysis of infants up to the time of cross-over, rescue treatment with HFJV was associated with lower mortality (RR 0.66, 95% CI 0.45 to 0.97). Researchers reported no significant differences in the incidence of CLD among survivors at 28 days of age, nor in the incidence of intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-08-29 23:18:27 +1000" MODIFIED_BY="[Empty name]">
<P>Study authors reported no significant differences in overall mortality between rescue high-frequency jet ventilation and conventional ventilation and presented highly imprecise results for important adverse effects such as intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.</P>
<P>The overall quality of evidence is affected by limitations in trial design and by imprecision due to the small number of infants in the included study. Existing evidence does not support the use of high-frequency jet ventilation as rescue therapy in preterm infants.</P>
<P>Studies that target populations at greatest risk and that have sufficient power to assess important outcomes are needed. These trials should incorporate long-term pulmonary and neurodevelopmental outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-25 12:04:35 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-08-29 23:46:32 +1000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-08-27 17:36:56 +1000" MODIFIED_BY="[Empty name]">
<P>Pulmonary disease continues to be a major cause of mortality and morbidity in very low birth weight infants despite increased use of antenatal steroids and surfactant therapy. In addition to immaturity, ventilator injury and oxygen toxicity are thought to be important factors in the pathogenesis of chronic pulmonary disease (<LINK REF="REF-Jobe-2000" TYPE="REFERENCE">Jobe 2000</LINK>). Animal studies (<LINK REF="REF-Barringer-1982" TYPE="REFERENCE">Barringer 1982</LINK>; <LINK REF="REF-Carlon-1983" TYPE="REFERENCE">Carlon 1983</LINK>; <LINK REF="REF-Hoff-1981" TYPE="REFERENCE">Hoff 1981</LINK>) and adult human studies (<LINK REF="REF-Carlon-1981" TYPE="REFERENCE">Carlon 1981</LINK>; <LINK REF="REF-Turnbull-1981" TYPE="REFERENCE">Turnbull 1981</LINK>) have provided evidence that high-frequency jet ventilation may reduce the severity of lung injury associated with mechanical ventilation.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-08-27 17:38:12 +1000" MODIFIED_BY="[Empty name]">
<P>High-frequency jet ventilators (HFJVs) deliver high-flow, short-duration pulses of pressurised gas directly into the upper airway through a specially designed endotracheal lumen. Pulses are delivered to the upper airway and are superimposed on a background gas flow from a conventional ventilator, which provides positive end-expiratory pressure (PEEP). Conventional breaths may be delivered in conjunction with jet ventilation. Systems operate at a rate of 150 to 600 breaths per minute. Exhalation is passive.</P>
</INTERVENTION>
<THEORY MODIFIED="2015-08-29 23:45:53 +1000" MODIFIED_BY="[Empty name]">
<P>High-frequency jet ventilation (HFJV) is substantially different from high-frequency oscillatory ventilation (HFOV), which uses an electromagnetically driven diaphragm to generate a sinusoidal pattern of pressure within the ventilatory circuit. Oscillating movement of the diaphragm causes active inspiratory and expiratory phases that drive the mixing of gases between circuits and alveoli. The amplitude of pressure generated by the diaphragm and mean airway pressure can be adjusted independently (<LINK REF="REF-Avery-2005" TYPE="REFERENCE">Avery 2005</LINK>). The major difference between HFJV and HFOV is seen in the inspiratory/expiratory ratios that they generate. Piston-driven HFOV devices have a mandatory 1:1 ratio. The SensorMedics HFOV is capable of a range of ratios but usually is used at a ratio of 1:2. The Bunnel HFJV is usually used at a 1:6 ratio. This extremely short I:E ratio makes it effective in treating patients with interstitial emphysema or a bronchopleural fistula.</P>
<P>Potential advantages of HFJV include use of small tidal volumes, effective management of ventilation and oxygenation and safer use of mean airway pressure, thereby reducing ventilator-related lung injury, improving gas exchange and decreasing oxygen requirements (<LINK REF="REF-Lampland-2007" TYPE="REFERENCE">Lampland 2007</LINK>). Some interventions will influence any ventilator strategy used in preterm infants. Surfactant, by its surface tension-reducing property, renders alveoli stable and prevents their collapse while increasing alveolar recruitment. Thus, use of surfactant has been reported to have a beneficial effect among infants with hyaline membrane disease (<LINK REF="REF-Soll-1998" TYPE="REFERENCE">Soll 1998</LINK>). High lung volume strategies have proved effective in reducing mortality and chronic lung disease. The adverse effect of necrotising tracheobronchitis, thought to be due to inadequate humidification of inspired gases (<LINK REF="REF-Elzouki-2011" TYPE="REFERENCE">Elzouki 2011</LINK>), has been reported in some animal studies. Therefore, we made the decision to conduct subgroup analyses based on use of surfactant; use of ventilation strategies to maintain optimal lung volumes, gestational age and weight; and use or no use of adequate humidification a priori.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-08-29 23:46:32 +1000" MODIFIED_BY="[Empty name]">
<P>This review updates the previous review of "Rescue high frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants" (<LINK REF="REF-Joshi-2006" TYPE="REFERENCE">Joshi 2006</LINK>). Included in this systematic review were trials in which participants were randomly assigned after they failed to adequately ventilate on conventional ventilation (CV), or when complications of CV developed or were likely to develop. Elective use of HFJV was assessed in another review (<LINK REF="REF-Bhuta-2002" TYPE="REFERENCE">Bhuta 2002</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-08-29 23:46:51 +1000" MODIFIED_BY="[Empty name]">
<P>To compare use of high-frequency jet ventilation (HFJV) versus conventional ventilation (CV) in preterm infants with severe pulmonary dysfunction.</P>
<P>Subgroup analyses include the following.</P>
<UL>
<LI>Trials with and without surfactant replacement therapy.</LI>
<LI>Trials with and without strategies to maintain lung volume.</LI>
<LI>Trials with infants of different gestational ages and birth weights (specific subgroups to include &lt; 28 weeks' gestation and &lt; 1000 grams).</LI>
<LI>Trials with and without adequate humidification of inspired gases.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-25 12:03:47 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-08-29 23:54:23 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-07-07 03:54:20 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials and quasi-randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-08-29 23:47:09 +1000" MODIFIED_BY="[Empty name]">
<P>Preterm infants at less than 35 weeks' gestational age at birth or with birth weight less than 2000 grams with severe pulmonary dysfunction, including pulmonary interstitial emphysema, and an unsatisfactory response to conventional ventilation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-08-29 23:52:37 +1000" MODIFIED_BY="[Empty name]">
<P>High-frequency jet ventilation (HFJV) used as rescue intervention in infants failing adequate conventional ventilation (CV), or presenting with complications such as pulmonary interstitial emphysema (PIE), and in preterm infants with severe pulmonary dysfunction (i.e. failing with adequate CV, or presenting complications such as pulmonary interstitial emphysema) for whom CV was used as continued therapy.</P>
<P>Trials assessing any of the following modes of ventilation were included.</P>
<P>HFJV.</P>
<UL>
<LI>High flow.</LI>
<LI>Short-duration pulses of pressurised gas directly into the upper airway.</LI>
<LI>Respiratory rate of 150 to 600 breaths per minute.</LI>
</UL>
<P>CV.</P>
<UL>
<LI>Time-cycled.</LI>
<LI>Pressure-limited ventilation through an endotracheal lumen.</LI>
<LI>Respiratory rate of approximately 30 to 80 breaths per minute.</LI>
</UL>
<P>Elective use of HFJV is not included here and is assessed in another review (<LINK REF="REF-Bhuta-2002" TYPE="REFERENCE">Bhuta 2002</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-08-29 23:54:23 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-08-28 17:33:50 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality at 28 to 30 days and at hospital discharge.</LI>
<LI>Chronic lung disease at 28 days (defined as oxygen supplementation at 28 days).</LI>
<LI>Chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation).</LI>
<LI>Chronic lung disease or death at 36 weeks' postmenstrual age.*</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-08-29 23:54:23 +1000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Pneumothorax.*</LI>
<LI>Pulmonary air leak syndromes (pneumothorax, pneumomediastinum, pulmonary interstitial emphysema).</LI>
<LI>Intraventricular haemorrhage (all grades with severe IVH defined as grades 3 and 4) (<LINK REF="REF-Papile-1978" TYPE="REFERENCE">Papile 1978</LINK>).</LI>
<LI>Periventricular echodensities.</LI>
<LI>Necrotising tracheobronchitis.</LI>
<LI>Sepsis.*</LI>
<LI>Necrotising enterocolitis (<LINK REF="REF-Bell-1978" TYPE="REFERENCE">Bell 1978</LINK>).*</LI>
<LI>Retinopathy of prematurity (<LINK REF="REF-ICCROP-2005" TYPE="REFERENCE">ICCROP 2005</LINK>).*</LI>
<LI>Long-term pulmonary outcome (including rehospitalisation for respiratory causes, asthma and/or pulmonary function testing).*</LI>
<LI>Long-term neurodevelopmental outcome (measured at approximately two years' corrected age; acceptable range 18 months to 28 months), including cerebral palsy, delayed neurodevelopment (Bayley Scales of Infant Development Mental Developmental Index &lt; 70), legal blindness (&lt; 20/200 visual acuity) and hearing deficit (aided or &lt; 60 dB on audiometric testing); impairment defined as including any of the aforementioned deficits.</LI>
<LI>Adverse events: airway obstruction (added post hoc).</LI>
</UL>
<P>*Added as an outcome in the 2015 update.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-08-29 23:56:20 +1000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-08-28 17:38:54 +1000" MODIFIED_BY="[Empty name]">
<P>The original search was conducted as described in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>In March 2015, we updated the search for published manuscripts through the following databases: Cumulative Index to Nursing and Allied Health Literature (CINAHL), EBSCOhost, EMBASE, MEDLINE via PubMed, <I>The Cochrane Library</I> from 2005 to 2015, using the following search terms: (oscillatory ventilation OR mechanical ventilation OR jet ventilation OR volume-targeted ventilation OR pressure-limited ventilation) AND (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial).</P>
<P>We searched for ongoing or registered clinical trials on clinicaltrials.gov and controlled-trials.com using the same search terms.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-08-29 23:56:20 +1000" MODIFIED_BY="[Empty name]">
<P>For the original review, information was obtained from experts in the field and from cross-references in published articles.</P>
<P>We conducted a search of the database of abstracts of the Pediatric Academic Societies from 2000 to 2015 using the term 'high-frequency jet ventilation'.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-09-25 12:03:47 +1000" MODIFIED_BY="[Empty name]">
<P>We used the standard review methods of the Neonatal Review Group, as documented in <I>The Cochrane Library</I>.</P>
<STUDY_SELECTION MODIFIED="2015-08-29 23:56:34 +1000" MODIFIED_BY="[Empty name]">
<P>We included all randomised and quasi-randomised controlled trials that fulfilled the selection criteria described in the previous section. Two review authors (MX and PO) reviewed results of the updated search and selected studies for inclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-08-29 23:57:09 +1000" MODIFIED_BY="[Empty name]">
<P>Each review author extracted data separately, then compared and resolved differences.</P>
<P>We requested additional data from one study author regarding 22 babies who were excluded post randomisation, but we could not obtain outcomes for these babies.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-09-25 12:03:47 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed the methodological quality of studies using the following key criteria: sequence generation,allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow-up and blinding of outcome measurement/assessment. For each criterion, assessment was yes, no or cannot determine. We included this information in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. In addition, review authors independently assessed the risk of bias for each study, using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed the methodological quality of studies by using the following criteria.</P>
<UL>
<LI>Sequence generation (evaluating possible selection bias): For each included study, we described the method used to generate the allocation sequence as adequate (any truly random process, e.g. random number table, computer random number generator); inadequate (any non-random process, e.g. odd or even date of birth, hospital or clinic record number); or unclear.</LI>
<LI>Allocation concealment (evaluating possible selection bias): For each included study, we described the method used to conceal the allocation sequence as adequate (e.g. telephone or central randomisation, consecutively numbered sealed opaque envelopes); inadequate (open random allocation, unsealed or non-opaque envelopes, alternation, date of birth); or unclear.</LI>
<LI>Blinding (evaluating possible performance bias): For each included study, we described the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We assessed methods as adequate, inadequate or unclear for participants; adequate, inadequate or unclear for study personnel; and adequate, inadequate or unclear for outcome assessors.</LI>
<LI>Incomplete outcome data (evaluating possible attrition bias through withdrawals, drop-outs, protocol deviations): For each included study and for each outcome, we described completeness of data, including attrition and exclusions from analysis. We stated whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with the total number of randomly assigned participants), reasons for attrition or exclusion when reported and whether missing data were balanced across groups or were related to outcomes. We assessed methods as adequate (&lt; 20% missing data); inadequate (&#8805; 20% missing data); or unclear.</LI>
<LI>Selective reporting bias: For each included study for which the protocol is available (through trial registers), we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed methods as adequate (when it was clear that all of the study&#8217;s prespecified outcomes and all expected outcomes of interest to the review had been reported); inadequate (when not all of the study&#8217;s prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; or the study failed to include results of a key outcome that would have been expected to have been reported); or unclear.</LI>
<LI>Other sources of bias. We noted other possible sources of bias (e.g. whether a potential source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias.</LI>
</UL>
<P>We made explicit judgements regarding whether studies were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to the criteria above, we assessed the likely magnitude and direction of bias and the likelihood that it would impact our findings. If needed, we planned to explore the impact of the level of bias by undertaking sensitivity analyses (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK> below).</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>We assessed the quality of evidence for the main comparison at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). This methodological approach considers randomised controlled trials (RCTs) as providing high-quality evidence that may be "down-rated" by limitations in any of five areas: design (risk of bias), consistency across studies, directness of the evidence, precision of estimates and presence of publication bias (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). The GRADE approach can be used to assess the quality of a body of evidence by one of the following four grades. High: We are very confident that the true effect lies close to that of the estimate of effect. Moderate: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect but may be substantially different. Low: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of effect. Very low: We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>).</P>
<P>Review authors independently assessed the quality of evidence found for outcomes identified as critical or important for clinical decision making: mortality at 28 to 30 days and at hospital discharge, chronic lung disease at 28 days (defined as oxygen supplementation at 28 days), chronic lung disease at 36 weeks' postmenstrual age (defined as supplemental oxygen at 36 weeks' gestation), chronic lung disease or death at 36 weeks' postmenstrual age, pulmonary air leak syndromes (pneumothorax, pneumomediastinum, pulmonary interstitial emphysema), intraventricular haemorrhage (all grades and grades 3 and 4) and long-term neurodevelopmental outcomes (including cerebral palsy, delayed neurodevelopment, legal blindness, hearing deficit and impairment defined as including any one of the aforementioned deficits).</P>
<P>When study authors did not take measures to ensure concealment of allocation, randomised assignment, completed follow-up or blinded outcome assessment, we downgraded the quality of the evidence because of design limitations (<LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). We evaluated consistency using similarity of point estimates, extent of overlap of confidence intervals and statistical criteria including tests for heterogeneity (I<SUP>2</SUP>). We downgraded the quality of the evidence when inconsistency across study results was present in a large and unexplained way (i.e. some studies suggest important benefit, and others no effect or harm without a clinical explanation) (<LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>). We assessed precision with the 95% confidence interval around the pooled estimation (<LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>). When trials were conducted in populations other than the target population, we downgraded the quality of the evidence because of indirectness (<LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>).</P>
<P>We entered data (i.e. pooled estimates of effects and corresponding 95% confidence Intervals) and explicit judgements for each of the assessed aspects described above into the <LINK REF="REF-Guideline-Development-Tool-2015" TYPE="REFERENCE">Guideline Development Tool 2015</LINK> - the software used to create 'Summary of findings' (SoF) tables. In footnotes or comments in the SoF table, we explained all judgements involved in assessment of study characteristics as described above (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-08-30 00:22:59 +1000" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Neonatal Review Group, including those for categorical data, and we used risk ratios (RRs) and risk differences (RDs). From 1/RD, we calculated the number needed to treat for an additional benefit (NNTB) or the number needed to treat for an additional harm (NNTH) to identify adverse effects, and we calculated their 95% confidence intervals (CIs). For continuous data, we used standardised mean differences (SMDs) with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-08-28 18:02:18 +1000" MODIFIED_BY="[Empty name]">
<P>For clinical outcomes such as episodes of sepsis, we analysed the data as proportions of neonates having one or more episodes.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-08-30 00:24:12 +1000" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted levels of attrition. We used sensitivity analysis to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect.</P>
<P>We performed all outcomes analyses on an intention-to-treat basis (i.e. we included in these analyses all participants randomly assigned to each group). The denominator for each outcome in each trial was the number randomly assigned minus the number of participants whose outcomes were known to be missing.</P>
<P>We requested additional data from one study author regarding 22 babies who were excluded post randomisation. We could not obtain outcomes for these babies from the study author.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-08-28 18:06:11 +1000" MODIFIED_BY="[Empty name]">
<P>We estimated treatment effects of individual trials and examined heterogeneity among trials by inspecting forest plots and quantifying the impact of heterogeneity using the I<SUP>2</SUP> statistic. We graded the degree of heterogeneity as &lt; 25% no heterogeneity; 25% to 49% low heterogeneity; 50% to 75% moderate heterogeneity; and &gt; 75% substantial heterogeneity. If we noted statistical heterogeneity (I<SUP>2</SUP> &gt; 50%), we explored possible causes (e.g. differences in study quality, participants, intervention regimens or outcome assessments).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-08-28 18:07:20 +1000" MODIFIED_BY="[Empty name]">
<P>We planned to assess possible publication bias and other biases using symmetry/asymmetry of funnel plots.</P>
<P>For included trials that were recently performed (and therefore prospectively registered), we explored possible selective reporting of study outcomes by comparing primary and secondary outcomes provided in the reports versus primary and secondary outcomes proposed at trial registration, using the websites www.clinicaltrials.gov and www.controlled-trials.com. If we found such discrepancies, we planned to contact the primary investigators to obtain missing data for outcomes prespecified at trial registration.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-08-28 18:08:30 +1000" MODIFIED_BY="[Empty name]">
<P>When meta-analysis was judged to be appropriate, we performed the analysis using Review Manager software (RevMan 2011), supplied by The Cochrane Collaboration. We used the Mantel-Haenszel method to determine estimates of typical risk ratios and risk differences. We included no continuous outcomes in this review.</P>
<P>We used the fixed-effect model for all meta-analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-08-30 00:26:12 +1000" MODIFIED_BY="[Empty name]">
<P>Planned subgroup analyses included the following.</P>
<UL>
<LI>Trials with and without surfactant replacement therapy.</LI>
<LI>Trials with and without strategies to maintain lung volume.</LI>
<LI>Trials with infants of different gestational ages and birth weights (specific subgroups to include &lt; 28 weeks' gestation and &lt; 1000 g).</LI>
<LI>Trials with and without adequate humidification of inspired gases.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-08-30 00:26:40 +1000" MODIFIED_BY="[Empty name]">
<P>We planned sensitivity analyses for situations that might affect interpretation of significant results (e.g. when risk of bias was associated with the quality of some of the included trials, when outcome data were missing). We determined that no such analyses were necessary for this review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-25 12:04:35 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-08-30 00:33:28 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-08-30 00:27:17 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review, a total of six potentially relevant trials were identified; five were randomised controlled trials (RCTs) (<LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK>; <LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>; <LINK REF="STD-Engle-1997" TYPE="STUDY">Engle 1997</LINK>; <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>; <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>), and one was a non-randomised study (<LINK REF="STD-Davis-1992" TYPE="STUDY">Davis 1992</LINK>). Of the five RCTs, only one met our inclusion criteria; three of the remaining trials (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>; <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>; <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) used HFJV as an elective intervention - not as "rescue" - and one (<LINK REF="STD-Engle-1997" TYPE="STUDY">Engle 1997</LINK>) was conducted in near term or term infants and did not match the population specified in the inclusion criteria.</P>
<P>From the updated search, we obtained 489 records; we screened 457 records after removing duplicates (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded a total of 455 records on the basis of review of titles and abstracts. We selected two as potentially eligible studies (<LINK REF="STD-Kushnir-2014" TYPE="STUDY">Kushnir 2014</LINK>; <LINK REF="STD-Plavka-2006" TYPE="STUDY">Plavka 2006</LINK>). Assessment of full text revealed that none of the remaining records matched the inclusion criteria for this review (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-08-30 00:29:25 +1000" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK> is a multi-centre RCT conducted from January 1987 to March 1989. <LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK> compared HFJV versus CV when given to infants younger than 7 days of age and weighing 750 grams or more at birth, in whom pulmonary interstitial emphysema (PIE) developed during CV. The primary outcome was improved PIE, clinical or radiographic, with reduced mean airway pressure (Paw). We included 144 infants in the analysis. Infants who did not respond to the initial mode of ventilation and met the specific criteria for treatment failure were permitted to cross over to other ventilation therapy.</P>
<P>Criteria for treatment failure included the following.</P>
<UL>
<LI>Worsening PIE, as demonstrated by significant radiographic worsening or by development of intractable air leaks, accompanied by deteriorating gas exchange requiring increasing ventilator support to maintain target blood gas values.</LI>
<LI>Lack of improvement, defined as no improvement in PIE after 96 hours, accompanied by deteriorating gas exchange.</LI>
<LI>Inadequate gas exchange during maximal support, including arterial oxygen tension &lt; 40 mmHg or arterial carbon dioxide tension &gt; 65 mmHg on mean airway pressure &gt; 15 cmH2O and fraction of inspired oxygen equal to one.</LI>
<LI>Acute deterioration, demonstrated by sudden worsening of participant status, so that continued participation in the study would be contrary to his or her best interest. In all, 39% of babies from the HFJV group were crossed over to CV, and 63% of babies from the CV group were crossed over to HFJV, when criteria for treatment failure were met. In this review, we analysed infants in the groups to which they were originally randomly assigned. None of the infants in the study received surfactant. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for details.</LI>
</UL>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-08-30 00:33:28 +1000" MODIFIED_BY="[Empty name]">
<P>In the original review, five studies were excluded (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>; <LINK REF="STD-Davis-1992" TYPE="STUDY">Davis 1992</LINK>; <LINK REF="STD-Engle-1997" TYPE="STUDY">Engle 1997</LINK>; <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>; <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
<P>
<LINK REF="STD-Engle-1997" TYPE="STUDY">Engle 1997</LINK> was not included because the study population was restricted to near term and term infants. <LINK REF="STD-Davis-1992" TYPE="STUDY">Davis 1992</LINK> was not included as it was neither randomised nor quasi-randomised.</P>
<P>In addition to the studies of <LINK REF="STD-Engle-1997" TYPE="STUDY">Engle 1997</LINK> and <LINK REF="STD-Davis-1992" TYPE="STUDY">Davis 1992</LINK>, three studies evaluating the effects of elective use of HFJV were excluded (<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK>; <LINK REF="STD-Keszler-1997" TYPE="STUDY">Keszler 1997</LINK>; <LINK REF="STD-Wiswell-1996" TYPE="STUDY">Wiswell 1996</LINK>). These studies are included in the systematic review, "Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants" (<LINK REF="REF-Bhuta-2002" TYPE="REFERENCE">Bhuta 2002</LINK>).</P>
<P>For this updated review, we excluded two studies (<LINK REF="STD-Kushnir-2014" TYPE="STUDY">Kushnir 2014</LINK>; <LINK REF="STD-Plavka-2006" TYPE="STUDY">Plavka 2006</LINK>).</P>
<P>
<LINK REF="STD-Kushnir-2014" TYPE="STUDY">Kushnir 2014</LINK> was an observational trial of infants being transitioned from HFOV to HFJV.</P>
<P>
<LINK REF="STD-Plavka-2006" TYPE="STUDY">Plavka 2006</LINK> was a single-centre (Prague), non-randomised pilot study in which 10 preterm infants with refractory respiratory failure (RRF) were assigned to rescue HFJV. Primary outcomes included reducing the PaCO2 and the oxygenation index (OI). The main reason for exclusion was that the study population did not match the inclusion criteria for this review. <LINK REF="STD-Plavka-2006" TYPE="STUDY">Plavka 2006</LINK> explored the effects of HFJV on oxygenation, ventilation and ease of extubation in preterm infants with evolving chronic lung disease (CLD) and refractory respiratory failure (RRF) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). </P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-08-28 18:24:00 +1000" MODIFIED_BY="[Empty name]">
<P>Details on the methodological quality of the included study are provided in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. Randomisation was adequate and allocation was concealed, but treatment was not blinded. Of 166 patients who were entered into the study, 22 (13%) were excluded from further consideration because of the presence of unrecognised exclusion criteria (nine patients), significant deviation from the protocol (eight), presence of a conflicting research protocol (three) or other reasons. We were not able to obtain from the study author data regarding babies excluded from each randomly assigned group.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-09-25 12:04:35 +1000" MODIFIED_BY="[Empty name]">
<P>The single included trial (<LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK>) reported on 144 infants (166 were randomly assigned). Results for critical and important outcomes follow here.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Mortality</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Overall mortality</HEADING>
<P>No statistically significant differences in overall mortality were noted between HFJV and CV groups (RR 1.03, 95% CI 0.64 to 1.66; RD 0.01, 95% CI -0.14 to 0.16). The quality of this evidence is low because of limitations in trial designed and imprecision of estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality before cross-over</HEADING>
<P>Mortality in the HFJV group was significantly lower than in the CV group (RR 0.66, 95% CI 0.45 to 0.97; RD -0.18, 95% CI -0.34 to -0.02). The quality of evidence for this outcome is moderate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality at 28 to 30 days</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mortality at hospital discharge</HEADING>
<P>Not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Chronic lung disease</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Chronic lung disease at 28 days</HEADING>
<P>No statistically significant differences were found in the incidence of CLD among survivors (RR 0.77, 95% CI 0.54 to 1.07; RD -0.16, 95% CI -0.35 to 0.04). The quality of this evidence is low because of limitations in trial design and imprecision of estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Chronic lung disease at 36 weeks' postmenstrual age</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Chronic lung disease or death at 36 weeks' postmenstrual age</HEADING>
<P>Not reported.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary air leak syndromes (pneumothorax, pneumomediastinum, pulmonary interstitial emphysema)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">New air leak</HEADING>
<P>No statistically significant differences were noted in the incidence of new air leaks (RR 0.76, 95% CI 0.46 to1.23; RD -0.09, 95% CI -0.24 to 0.06). The quality of this evidence is low because of limitations in trial design and imprecision of estimates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pneumothorax</HEADING>
<P>Not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intraventricular haemorrhage</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Intraventricular haemorrhage all grades</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Intraventricular haemorrhage grades 3 and 4</HEADING>
<P>No statistically significant differences were noted in the incidence of severe IVH (grades 3 and 4) (RR 0.74, 95% CI 0.42 to1.28; RD - 0.09, 95% CI -0.26 to 0.07). The incidence of new IVH in infants assessed was lower in the rescue HFJV group, but this finding was not statistically significant (RR 0.49, 95% CI 0.19 to1.24). The quality of this evidence is low because of limitations in trial design and imprecision of estimates.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Periventricular leukomalacia (cystic or haemorrhage) and periventricular echodensities</HEADING>
<P>
<LINK REF="STD-Keszler-1991" TYPE="STUDY">Keszler 1991</LINK> did not report on these outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Necrotising tracheobronchitis</HEADING>
<P>No statistically significant differences were noted in the incidence of necrotising tracheobronchitis at autopsy in 17 infants (RR 1.33, 95% CI 0.29 to 6.06; RD 0.08, 95% CI -0.35 to 0.51).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Airway obstruction</HEADING>
<P>No statistically significant differences were noted between the two groups (RR 3.78, 95% CI 0.43 to 33.03; RD 0.04, 95% CI -0.02 to 0.10).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sepsis</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Necrotising enterocolitis</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Retinopathy of prematurity</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term pulmonary outcomes (including rehospitalisation for respiratory causes, asthma and/or pulmonary function testing)</HEADING>
<P>Not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term neurodevelopmental outcomes</HEADING>
<P>Not reported.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-08-30 00:43:56 +1000" MODIFIED_BY="[Empty name]">
<P>Only one trial satisfied the eligibility criteria and was included in this review. It was conducted in the late 1980s, and none of the infants in the study received exogenous surfactant. The study was designed to investigate short-term pulmonary outcomes such as resolution of pulmonary interstitial emphysema (PIE) associated with radiographic improvement. The cross-over that was permitted hampered the ability of investigators to demonstrate an advantage of one ventilator over the other in reducing important complications.</P>
<P>Regarding outcomes identified as critical or important for clinical decision making, the included study showed no differences in overall mortality (including survival after cross-over) among infants treated with high-frequency jet ventilation (HFJV) versus conventional ventilation (CV). Survival by original assignment did not differ between groups; however, because of the cross-over design of the trial and the high cross-over rate, the meaning of data on this important outcome is unclear. Mortality up until the point of cross-over was lower in the HFJV group than in the group given CV.</P>
<P>Although reduction in the incidence of chronic lung disease (CLD) at 28 days was a potential benefit, this finding was not statistically significant. A possible explanation for this is that the intervention in infants with severe respiratory failure and established barotrauma may have come too late to have an impact on the incidence of CLD.</P>
<P>The trial reported on new pulmonary air leak syndrome but failed to show statistically significant differences in risk of pneumothorax, pneumomediastinum or PIE between HFJV and CV.</P>
<P>Among desirable short-term and long-term neurological outcomes, the included trial reported only on rates of severe intraventricular haemorrhage (IVH; grades 3 and 4), but lack of precision in estimates permits no conclusions on the effects of HFJV on this outcome. Researchers did not assess periventricular leukomalacia (PVL) and long-term neurodevelopmental outcomes.</P>
<P>The overall quality of evidence among these critical outcomes ranges from low to moderate because of imprecision of estimates and lack of blinding of participants and of outcome assessors. For CLD, pulmonary air leak syndrome and IVH, the quality of evidence is low, which means that our confidence in the effect estimate is limited, and it may be substantially different from the true effect.</P>
<P>The included trial reported on other important pulmonary outcomes such as incidence of airway obstruction and necrotising tracheobronchitis, but estimates of the effects of assessed interventions on these outcomes are very imprecise, leaving it unclear whether HFJV leads to significantly more or less airway injury.</P>
<P>No evidence showed the effect that HFJV may have on other important neonatal outcomes, including sepsis, necrotising enterocolitis, retinopathy of prematurity or long-term pulmonary outcomes such as rehospitalisation for respiratory causes, asthma or pulmonary function.</P>
<P>Evidence on effects of HFJV as rescue intervention for severe pulmonary dysfunction was derived from just from one trial involving 144 infants. Limitations in trial design such as lack of blinding of outcome assessment; reports of imprecise results for most assessed outcomes; and failure to report important long-term neurodevelopmental outcomes do not support use of this intervention in neonates.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-08-30 00:46:18 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-08-30 00:45:07 +1000" MODIFIED_BY="[Empty name]">
<P>This study showed no significant differences in overall mortality between rescue high-frequency jet ventilation and conventional ventilation; investigators reported highly imprecise results for adverse effects such as intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis, which do not allow conclusions regarding effects of high-frequency jet ventilation as rescue intervention on these important safety outcomes.</P>
<P>The overall quality of evidence is related to the fact that the study was done before surfactant therapy was introduced and before antenatal steroids (which have shown significant impact in lung disease and survival of preterm infants) were used routinely, as well as to limitations in trial design and imprecision resulting from the small number of infants included in the study.</P>
<P>Thus, existing evidence is of low quality and does not support the use of high-frequency jet ventilation as rescue therapy in preterm infants.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-08-30 00:46:18 +1000" MODIFIED_BY="[Empty name]">
<P>New studies assessing high-frequency jet ventilation as rescue therapy for preterm infants under current practices in neonatal care units could be useful for determining the real effects of this intervention. These new studies should have enough power to define the effects of the intervention on different subgroups of infants according to use of surfactant and prenatal steroids, and should undertake comparisons of conventional ventilation versus more gentle ventilation modes currently available, such as trigger modes and volume guarantee. These trials should incorporate long-term neurodevelopmental outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-10-13 03:03:08 +1000" MODIFIED_BY="[Empty name]">
<P>From the original review: We thank Martin Keszler for answering our queries about the study, and David Henderson-Smart, who participated in protocol development.</P>
<P>We acknowledge Prof. David J. Henderson-Smart (deceased), Dr. Tushar Bhuta and Dr. Vinay H. Joshi for their previous work on this review.</P>
<P>The review authors thank Colleen Ovelman, Information Specialist from the Cochrane Neonatal Group, for running new searches for this review update.</P>
<P>The Faculty of Medicine of the Pontificia Universidad Javeriana, Bogotá, Colombia, supported the time dedicated by María Ximena Rojas to update this review as part of an agreement with The Cochrane Collaboration. Paola Orrego is a medical student participant from the Systematic Reviews Seed Research Program of the Cochrane Colaborating Centre "Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine of the Pontificia Universidad Javeriana, Bogotá, Colombia".</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-08-30 03:41:38 +1000" MODIFIED_BY="[Empty name]">
<P>None of the authors declared that they had a conflict of interest over the past three years.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-08-30 03:46:15 +1000" MODIFIED_BY="[Empty name]">
<P>Vinay Joshi and Tushar Bhuta wrote the first version of this review.</P>
<P>María Ximena Rojas-Reyes and Paola Orrego-Rojas drafted the update protocol and conducted the updating process.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-08-30 03:51:59 +1000" MODIFIED_BY="[Empty name]">
<P>New outcomes were added to the 2015 update (chronic lung disease or death at 36 weeks' postmenstrual age, pneumothorax, sepsis, necrotising enterocolitis (<LINK REF="REF-Bell-1978" TYPE="REFERENCE">Bell 1978</LINK>), retinopathy of prematurity (<LINK REF="REF-ICCROP-2005" TYPE="REFERENCE">ICCROP 2005</LINK>), long-term pulmonary outcomes (including rehospitalisation for respiratory causes, asthma and/or pulmonary function testing), long-term neurodevelopmental outcomes (measured at approximately two years' corrected age; acceptable range 18 months to 28 months) including cerebral palsy, delayed neurodevelopment (Bayley Scales of Infant Development Mental Developmental Index &lt; 70), legal blindness (&lt; 20/200 visual acuity) and hearing deficit (aided or &lt; 60 dB on audiometric testing), or impairment defined as having any one of the aforementioned deficits, and adverse events including airway obstruction.</P>
<P>GRADE assessment and a 'Summary of findings' table were added to the 2015 update.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-08-30 03:55:05 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-08-30 03:55:05 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-08-30 03:55:05 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Keszler-1991" MODIFIED="2015-08-30 03:55:05 +1000" MODIFIED_BY="[Empty name]" NAME="Keszler 1991" YEAR="11991">
<REFERENCE MODIFIED="2015-08-30 03:55:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keszler M, Donn SM, Bucciarelli RL, Alverson DC, Hart M, Lunyong V, et al</AU>
<TI>Multicenter controlled trial comparing high-frequency jet ventilation and conventional mechanical ventilation in newborn infants with pulmonary interstitial emphysema</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>119</VL>
<NO>1 Pt 1</NO>
<PG>85-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-08-29 21:05:42 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Carlo-1990" MODIFIED="2013-07-24 01:09:02 +1000" MODIFIED_BY="[Empty name]" NAME="Carlo 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-07-24 01:09:02 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carlo WA, Siner B, Chatburn RL, Robertson S, Martin RJ</AU>
<TI>Early randomized intervention with high-frequency jet ventilation in respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<NO>5</NO>
<PG>765-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1992" MODIFIED="2013-07-24 01:18:07 +1000" MODIFIED_BY="[Empty name]" NAME="Davis 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-07-24 01:18:07 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis JM, Richter SE, Kending JW, Notter RH</AU>
<TI>High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory failure</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>2</NO>
<PG>108-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engle-1997" MODIFIED="2013-07-24 02:20:26 +1000" MODIFIED_BY="[Empty name]" NAME="Engle 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-24 02:20:26 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engle WA, Yoder MC, Andreoli SP, Darragh RK, Langefeld CD, Hui SL</AU>
<TI>Controlled prospective randomized comparison of high-frequency jet ventilation and conventional ventilation in neonates with respiratory failure and persistent pulmonary hypertension</TI>
<SO>Journal of Perinatology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keszler-1997" MODIFIED="2013-07-24 02:21:20 +1000" MODIFIED_BY="[Empty name]" NAME="Keszler 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-07-24 02:21:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keszler M, Modanlou HD, Brudno DS, Clark FI, Cohen RS, Ryan RM, et al</AU>
<TI>Multicenter controlled clinical trial of high-frequency jet ventilation in preterm infants with uncomplicated respiratory distress syndrome</TI>
<SO>Pediatrics</SO>
<YR>1997</YR>
<VL>100</VL>
<NO>4</NO>
<PG>593-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kushnir-2014" MODIFIED="2015-08-29 20:57:01 +1000" MODIFIED_BY="[Empty name]" NAME="Kushnir 2014" YEAR="&lt;span class=&quot;inserted&quot; modified=&quot;2015-06-18 18:43:00 -0500&quot; modified_by=&quot;[Empty name]&quot;&gt;2014&lt;/span&gt;">
<REFERENCE MODIFIED="2015-08-29 20:57:01 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Kushnir A, Kemble N, Saslow J</AU>
<TI>Oxygenation in neonates with hypoxemic refractory respiratory failure (HRRF) after switching from high-frequency oscillatory ventilator (HFOV) to high-frequency jet ventilator (HFJV) [abstract]</TI>
<SO>Pediatric Academic Societies</SO>
<YR>2014</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plavka-2006" MODIFIED="2013-07-24 01:23:21 +1000" MODIFIED_BY="[Empty name]" NAME="Plavka 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-07-24 01:23:21 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plavka R, Dokoupilová M, Pazderová L, Kopecký P, Sebron V, Zapadlo M, et al</AU>
<TI>High-frequency jet ventilation improves gas exchange in extremely immature infants with evolving chronic lung disease</TI>
<SO>American Journal of Perinatology</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>8</NO>
<PG>467-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiswell-1996" MODIFIED="2015-08-29 21:05:42 +1000" MODIFIED_BY="[Empty name]" NAME="Wiswell 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-08-29 21:05:42 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiswell TE, Graziani LJ, Kornhauser MS, Cullen J, Merton DA, McKee L, et al</AU>
<TI>High-frequency jet ventilation in the early management of respiratory distress syndrome is associated with a greater risk for adverse outcomes</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>98</VL>
<NO>6 Pt 1</NO>
<PG>1035-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-07-08 23:50:03 +1000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-08-29 21:20:16 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-08-29 21:20:16 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Avery-2005" MODIFIED="2015-08-29 21:11:43 +1000" MODIFIED_BY="[Empty name]" NAME="Avery 2005" TYPE="BOOK">
<AU>Avery GB, MacDonald MG, Seshia MMK, Mullett MD</AU>
<SO>Avery&#8217;s Neonatology: Pathophysiology &amp; Management of the Newborn</SO>
<YR>2005</YR>
<EN>6th</EN>
<PB>Lippincott Williams &amp; Wilkins</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS MODIFIED="2015-06-18 04:04:52 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Barringer-1982" MODIFIED="2013-07-24 01:25:06 +1000" MODIFIED_BY="[Empty name]" NAME="Barringer 1982" TYPE="JOURNAL_ARTICLE">
<AU>Barringer M, Meredith J, Prough D, Gibson R, Blinkhorn R</AU>
<TI>Effectiveness of high-frequency jet ventilation in management of experimental bronchopleural fistula</TI>
<SO>American Surgeon</SO>
<YR>1982</YR>
<VL>48</VL>
<NO>12</NO>
<PG>610-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1978" MODIFIED="2015-07-07 04:38:29 +1000" MODIFIED_BY="[Empty name]" NAME="Bell 1978" TYPE="JOURNAL_ARTICLE">
<AU>Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al</AU>
<TI>Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging</TI>
<SO>Annals of Surgery</SO>
<YR>1978</YR>
<VL>187</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhuta-2002" MODIFIED="2008-10-17 01:43:07 +1000" MODIFIED_BY="[Empty name]" NAME="Bhuta 2002" TYPE="COCHRANE_REVIEW">
<AU>Bhuta T, Henderson-Smart DJ</AU>
<TI>Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-10-17 01:43:07 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-17 01:43:07 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000328"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Carlon-1981" MODIFIED="2013-07-24 01:32:05 +1000" MODIFIED_BY="[Empty name]" NAME="Carlon 1981" TYPE="JOURNAL_ARTICLE">
<AU>Carlon GC, Kahn RC, Howland WS, Ray C Jr, Turnbull AD</AU>
<TI>Clinical experience with high frequency jet ventilation</TI>
<SO>Critical Care Medicine</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carlon-1983" MODIFIED="2013-07-24 01:30:33 +1000" MODIFIED_BY="[Empty name]" NAME="Carlon 1983" TYPE="JOURNAL_ARTICLE">
<AU>Carlon GC, Griffin J, Ray C Jr, Groeger JS, Patrick K</AU>
<TI>High frequency jet ventilation in experimental airway disruption</TI>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>5</NO>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elzouki-2011" MODIFIED="2015-08-29 21:13:20 +1000" MODIFIED_BY="[Empty name]" NAME="Elzouki 2011" TYPE="BOOK_SECTION">
<AU>Kaam AH, van Keszler M</AU>
<TI>Mechanical ventilation: HFV</TI>
<SO>Textbook of Clinical Pediatrics [Internet]</SO>
<YR>2012</YR>
<PG>245-50</PG>
<ED>Elzouki AY, Harfi HA, Nazer HM, Stapleton FB, Oh W, Whitley RJ</ED>
<PB>Springer</PB>
<CY>Berlin, Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GradePro-2014" MODIFIED="2015-08-29 21:14:35 +1000" MODIFIED_BY="[Empty name]" NAME="GradePro 2014" TYPE="COMPUTER_PROGRAM">
<TI>GradePro [Version 3.2 for Windows]</TI>
<YR>2014</YR>
<PB>McMaster University</PB>
<CY>Hamilton, Ontario, Canada</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guideline-Development-Tool-2015" MODIFIED="2015-08-29 21:15:16 +1000" MODIFIED_BY="[Empty name]" NAME="Guideline Development Tool 2015" TYPE="COMPUTER_PROGRAM">
<TI>Guideline Development Tool</TI>
<YR>2015</YR>
<PB>McMaster University and Evidence Prime Inc.</PB>
<CY>Hamilton, Ontario, Canada</CY>
<IDENTIFIERS MODIFIED="2015-06-19 10:43:05 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-19 10:42:45 +1000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="http://www.guidelinedevelopment.org/"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-08-29 21:15:53 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2015-05-14 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21803546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2015-08-29 21:16:16 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2015-05-14 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21839614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2015-08-29 21:16:40 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2015-05-14 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21195583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2015-08-29 21:16:58 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2015-05-14 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21247734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2015-08-29 21:17:19 +1000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2015-05-14 00:34:56 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21802903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-08-29 21:17:46 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoff-1981" MODIFIED="2013-07-24 02:23:01 +1000" MODIFIED_BY="[Empty name]" NAME="Hoff 1981" TYPE="JOURNAL_ARTICLE">
<AU>Smith RB, Cutaia F, Hoff BH, Babinski M, Gelineau J</AU>
<TI>Long-term transtracheal high frequency ventilation in dogs</TI>
<SO>Critical Care Medicine</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>4</NO>
<PG>311-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICCROP-2005" MODIFIED="2015-07-07 04:39:28 +1000" MODIFIED_BY="[Empty name]" NAME="ICCROP 2005" TYPE="JOURNAL_ARTICLE">
<AU>International Committee for the Classification of Retinopathy of Prematurity</AU>
<TI>The International Classification of Retinopathy of Prematurity revisited</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2005</YR>
<VL>123</VL>
<NO>7</NO>
<PG>991-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jobe-2000" NAME="Jobe 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jobe AH, Ikegami M</AU>
<TI>Lung development and function in preterm infants in the surfactant era</TI>
<SO>Annual Review of Physiology</SO>
<YR>2000</YR>
<VL>62</VL>
<PG>825-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lampland-2007" MODIFIED="2015-08-29 21:18:40 +1000" MODIFIED_BY="[Empty name]" NAME="Lampland 2007" TYPE="JOURNAL_ARTICLE">
<AU>Lampland AL, Mammel MC</AU>
<TI>The role of high-frequency ventilation in neonates: evidence-based recommendations</TI>
<SO>Clinical Perinatology</SO>
<YR>2007</YR>
<VL>Mar 34</VL>
<NO>1</NO>
<PG>129&#8211;44, viii</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papile-1978" MODIFIED="2015-07-07 04:39:01 +1000" MODIFIED_BY="[Empty name]" NAME="Papile 1978" TYPE="JOURNAL_ARTICLE">
<AU>Papile LA, Burstein J, Burstein R, Koffler H</AU>
<TI>Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<NO>4</NO>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2015-08-29 21:20:16 +1000" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GRADE Working Group</AU>
<TI>RADE Handbook for Grading Quality of Evidence and Strength of Recommendations</TI>
<SO>www.guidelinedevelopment.org/handbook.</SO>
<YR>Updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soll-1998" MODIFIED="2015-06-25 01:35:30 +1000" MODIFIED_BY="[Empty name]" NAME="Soll 1998" TYPE="COCHRANE_REVIEW">
<AU>Soll R</AU>
<TI>Synthetic surfactant for respiratory distress syndrome in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-06-18 06:50:55 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-18 06:50:55 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001149"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Turnbull-1981" MODIFIED="2013-07-24 02:18:55 +1000" MODIFIED_BY="[Empty name]" NAME="Turnbull 1981" TYPE="JOURNAL_ARTICLE">
<AU>Turnbull AD, Carlon G, Howland WS, Beattie EJ Jr</AU>
<TI>High-frequency jet ventilation in major airway or pulmonary disruption</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1981</YR>
<VL>32</VL>
<NO>5</NO>
<PG>468-74</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-23 03:20:39 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Joshi-2006" MODIFIED="2015-07-23 03:20:39 +1000" MODIFIED_BY="[Empty name]" NAME="Joshi 2006" TYPE="COCHRANE_REVIEW">
<AU>Joshi VH, Bhuta T</AU>
<TI>Rescue high frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-07-23 03:20:39 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-23 03:20:39 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000437.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-08-30 03:54:38 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-08-29 21:26:32 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-08-29 21:26:32 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keszler-1991">
<CHAR_METHODS MODIFIED="2015-08-29 11:20:54 +1000" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial, enrolment between January 1987 and March 1989<BR/>Concealment at randomisation - yes. Randomisation was performed centrally by calling a 24-hour hotline<BR/>Blinding of intervention - no<BR/>Complete follow-up - 22 of 166 infants were excluded after initial randomisation<BR/>Blinding of outcome assessment - no<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-08-29 11:22:08 +1000" MODIFIED_BY="[Empty name]">
<P>166 preterm infants younger than 7 days of age and weighing &#8804; 750 grams at birth, with pulmonary interstitial emphysema. Eligible infants were stratified by birth weight and by severity of illness. Among 144 infants analysed, mean birth weight was 1340 grams and mean gestational age at study entry was 29.3 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-08-29 21:26:32 +1000" MODIFIED_BY="[Empty name]">
<P>High-frequency jet ventilation (HFJV) with 400 to 450 cycles/min (treatment group), conventional ventilation (CV) with rates of 60 to 100 breaths/min, short inspiratory time (control group). 70 infants were assigned to CV, and 74 infants to HFJV. Cross-over to alternate therapy was allowed if infants failed allocated ventilator therapy (Treatment failure was defined as worsening pulmonary interstitial emphysema (PIE), lack of improvement, inadequate gas exchange during maximal support or acute deterioration)<BR/>Effective gas heating and humidification system</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-08-29 21:26:21 +1000" MODIFIED_BY="[Empty name]">
<P>Mortality at 28 to 30 days, success in the original assignment, chronic lung disease (CLD) at 28 to 30 days, intraventricular haemorrhage (IVH) (grades 3 and 4), new air leak, necrotising tracheobronchitis, airway obstruction, CLD in survivors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-08-29 11:23:55 +1000" MODIFIED_BY="[Empty name]">
<P>Prenatal steroids were not reported. None of the babies received exogenous surfactant. Study was supported by Bunnell Inc</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-08-30 03:54:38 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-08-30 03:54:26 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carlo-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-30 03:54:26 +1000" MODIFIED_BY="[Empty name]">
<P>Elective high-frequency jet ventilation (HFJV)</P>
<P>
<LINK REF="STD-Carlo-1990" TYPE="STUDY">Carlo 1990</LINK> randomly selected 42 infants with clinical and radiographic evidence of severe respiratory distress syndrome to receive HFJV or conventional ventilation (CV)</P>
<P>RESULTS: Mortality rates (19% among infants receiving HFJV vs 24% among infants receiving CV), incidence of air leaks (48% vs 52%), bronchopulmonary dysplasia (39% vs 41%), intraventricular haemorrhage (33% vs 43%) and assignment cross-overs (14% vs 24%) did not differ significantly between treatment groups. We conclude that early use of HFJV does not prevent or substantially reduce mortality or morbidity rates associated with assisted ventilation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-29 18:27:53 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davis-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-29 18:27:53 +1000" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial</P>
<P>Twenty-eight newborn infants (birth weight 2.4 ± 1.1 kg; gestational age 34.6 ± 6.1 weeks) with respiratory distress syndrome (RDS), meconium aspiration syndrome or pneumonia, who deteriorated in spite of optimal conventional mechanical ventilation (CMV) and exogenous surfactant therapy, were treated with high-frequency jet ventilation (HFJV) and continued surfactant therapy</P>
<P>Infants had to have a limited response to surfactant therapy and conventional ventilation, and had to meet clinical criteria that confirmed clinical deterioration and severity of illness</P>
<P>Participants initially responded to HFJV alone with significant improvement in several respiratory variables, but their condition deteriorated subsequently and they received additional doses of exogenous surfactant on HFJV. Exogenous surfactant and HFJV resulted in significant and sustained improvement in several respiratory variables</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-29 21:29:36 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engle-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-29 21:29:36 +1000" MODIFIED_BY="[Empty name]">
<P>The study population was restricted to term and near term neonates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-29 21:39:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keszler-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-29 21:39:23 +1000" MODIFIED_BY="[Empty name]">
<P>Multi-centre, randomised, controlled clinical trial of high-frequency jet ventilation (HFJV) and conventional ventilation (CV). Participants were to remain on assigned therapy for 14 days or until extubation, whichever came first. Cross-over from CV to HFJV was allowed if bilateral pulmonary interstitial emphysema or bronchopleural fistula developed. Participants could cross over to the other ventilatory mode if failure criteria were met. The optimal lung volume strategy was mandated for HFJV by protocol to provide alveolar recruitment and optimise lung volume and ventilation/perfusion matching, while minimising pressure amplitude and O<SUB>2</SUB> requirements. CV management was not controlled by protocol</P>
<P>SETTING: 8 tertiary neonatal intensive care units</P>
<P>PARTICIPANTS: Preterm infants with birth weights between 700 and 1500 grams and gestational age &lt; 36 weeks who required mechanical ventilation with fraction of inspired oxygen (FIO<SUB>2</SUB>) &gt; 0.30 at 2 to 12 hours after surfactant administration, received surfactant by 8 hours of age, were &lt; 20 hours old and had been ventilated for &lt; 12 hours</P>
<P>OUTCOME MEASURES: Primary outcome variables were bronchopulmonary dysplasia (BPD) at 28 days' and 36 weeks' postconceptional age. Secondary outcome variables were survival, gas exchange, airway pressures, air leak, intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL) and other non-pulmonary complications</P>
<P>RESULTS: A total of 130 participants were included in the final analysis; 65 were randomly assigned to HFJV and 65 to CV. Groups were of comparable birth weight, gestational age, severity of illness, postnatal age and other demographics. The incidence of BPD at 36 weeks' postconceptional age was significantly lower in babies randomly assigned to HFJV compared with CV (20.0% vs 40.4%). The need for home oxygen was significantly lower in infants receiving HFJV compared with CV (5.5% vs 23.1%). Survival, incidence of BPD at 28 days, retinopathy of prematurity, air leak, pulmonary haemorrhage, grade 1 to 2 IVH and other complications were similar</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-30 03:54:38 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kushnir-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-30 03:54:38 +1000" MODIFIED_BY="[Empty name]">
<P>OBJECTIVE: to study the response of infants with hypoxaemic respiratory failure whose respiratory support was switched from high-frequency oscillatory ventilation (HFOV) to high-frequency jet ventilation (HFJV)</P>
<P>Retrospective data analysis of 15 infants from 1/2011 to 9/2013 was conducted for infants with hypoxaemic refractory respiratory failure (HRRF) who were started on HFJV. Data were collected while patients were being switched from HFOV to HFJV and for 24 hours after the switch</P>
<P>PARTICIPANTS: patients being switched from HFOV to HFJV</P>
<P>OUTCOME MEASURES: Ventilator settings, oxygen saturations and oxygenation index (OI) were collected every 2 hours for 8 hours, then every 4 hours for 16 hours. Respiratory failure was defined as OI &gt; 20, with mean airway pressure (MAP) providing optimum lung expansion on HFOV. Oxygenation settings on HFOV were compared with settings on HFJV initially and during the first 24 hours</P>
<P>Over 20 months, 15 neonates with mean gestational age of 25.1 weeks and birth weight of 723 grams qualified for the study. A significant decrease in the fraction of inspired oxygen (FiO2) was noted at 30 minutes (0.93 to 0.78, P value = 0.01), within the first 12 hours (0.64, P value &lt; 0.001) and within 24 hours (0.57, P value &lt; 0.001) following the change to HFJV. A decrease in the OI was observed within the first 12 hours (37 to 19.6, P value = 0.006) and within 24 hours (17.8, P value = 0.005) post change. MAP decreased within the first 24 hours (14.4 to 12.8, P value = 0.06). Median postnatal age at change to HFJV was 15 days, and patients remained on the jet ventilator for an average of 12 days</P>
<P>E-PAS2014:2937.522</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-29 21:35:35 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Plavka-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-29 21:35:35 +1000" MODIFIED_BY="[Empty name]">
<P>Evaluated the effects of high-frequency jet ventilation (HFJV) on oxygenation, ventilation and ease of extubation in preterm infants with evolving chronic lung disease (CLD) and refractory respiratory failure (RRF) in a non-randomised pilot trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-29 21:39:54 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiswell-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-29 21:39:54 +1000" MODIFIED_BY="[Empty name]">
<P>73 premature infants who met the inclusion criteria (gestational age &lt; 33 weeks, birth weight &gt; 500 grams, age &lt; 24 hours, need for assisted ventilation with peak inspiratory pressure &gt; 16 and fraction of inspired oxygen (FIO<SUB>2</SUB>) &gt; 0.30 and roentgenographic evidence of respiratory distress syndrome) were randomly assigned to conventional (n = 36) or to high-frequency jet (n = 37) ventilation (HFJV). Attempts were made to maintain infants on the assigned ventilator for &#8805; 7 days unless they could be extubated or could meet cross-over criteria</P>
<P>RESULTS: The 2 groups of infants were similar in all obstetrical, perinatal and neonatal demographic characteristics. Mean birth weight and gestational age in the conventional group were 930 g and 26.6 weeks, and in the HFJV group, 961 g and 26.9 weeks. Infants were randomly assigned at similar ages (7.1 and 7.3 hours of life, respectively). Their prerandomisation ventilator settings and arterial blood gases were nearly identical. No differences were noted in pulmonary outcomes (occurrence of air leaks, need for oxygen or ventilation at 36 weeks' postmenstrual age), and no differences were reported in the mean number of days oxygen was required, the number of days ventilated or the length of hospital stay. Infants ventilated with HFJV were significantly more likely to develop cystic periventricular leukomalacia (10 vs 2, P value = .022) or to have a poor outcome (grade 4 haemorrhage, cystic periventricular leukomalacia or death) (17 vs 7, P value = .016). Logistic regression analysis revealed HFJV to be a significant independent predictor of both cystic periventricular leukomalacia and a poor outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-07-08 23:50:03 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-08-29 11:29:55 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-07-21 05:32:18 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-08-29 11:29:47 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-08-29 11:29:47 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION>
<P>Concealment at randomisation - yes. Randomisation performed centrally by calling 24-hour hotline<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-08-29 11:29:50 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2015-08-29 11:29:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION>
<P>Blinding of intervention - no<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-07-22 23:36:39 +1000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-07-22 23:36:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-07-09 03:38:33 +1000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-09 03:38:33 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION>
<P>No blinded outcome assessment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-08-29 11:29:55 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-08-29 11:29:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Keszler-1991">
<DESCRIPTION>
<P>22 of 166 infants were excluded after initial randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-07-22 23:36:53 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-09-25 12:09:01 +1000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-09-25 12:09:01 +1000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-08-29 20:05:08 +1000" MODIFIED_BY="[Empty name]">Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>preterm infants with severe pulmonary dysfunction<BR/>
<B>Setting: </B>neonatal intensive care unit in the United States<BR/>
<B>Intervention: </B>high-frequency jet ventilation<BR/>
<B>Comparison: </B>conventional ventilation</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with conventional ventilation</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with high-frequency jet ventilation</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Overall mortality</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>314 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>324 per 1000<BR/>(201 to 522)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 1.03<BR/>(0.64 to 1.66)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>144<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#9711;&#9711;<BR/>LOW<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Downgraded 2 levels because of:</P>
<P/>
<P>&#8226; serious risk of bias (limitations in trial design due to high cross-over rates between alternative therapies).</P>
<P/>
<P>&#8226; serious imprecision (95% confidence interval includes both no effect and appreciable harm. Total number of events does not meet optimal information size)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Mortality before cross-over</P>
</TD>
<TD VALIGN="TOP">
<P>529 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>349 per 1000</P>
<P>(238 to 513)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.66 (0.45 to 0.97)</P>
</TD>
<TD VALIGN="TOP">
<P>144 (1 RCT)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#9711;<BR/>MODERATE<SUP>a</SUP>
</P>
</TD>
<TD>
<P>Downgraded 1 level because of:</P>
<P/>
<P>&#8226; serious imprecision (total number of participants does not meet the optimal information size; OIS is &gt; 260 participants)</P>
<P/>
<P>&#8226; reasons other than limitations in study design, as mortality before cross-over is not affected by design limitations (see above)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Chronic lung disease at 28 days of birth (CLD 28 days)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>667 per 1000</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>513 per 1000<BR/>(360 to 713)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.77<BR/>(0.54 to 1.07)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>97<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#9711;&#9711;<BR/>LOW<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Downgraded 2 levels because of:</P>
<P/>
<P>&#8226; serious risk of bias (limitations in trial design (lack of blinding of outcome assessment)</P>
<P/>
<P>&#8226; serious imprecision (95% confidence interval includes both no effect and appreciable harm. Total number of events does not meet optimal information size)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Pulmonary air leak (new)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>357 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>271 per 1000<BR/>(164 to 439)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.76<BR/>(0.46 to 1.23)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>144<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#9711;&#9711;<BR/>LOW<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Downgraded 2 levels because of:</P>
<P/>
<P>&#8226; serious risk of bias (limitations in trial design (lack of blinding of participants, providers and outcome assessor)</P>
<P/>
<P>&#8226; serious imprecision (95% confidence interval includes both no effect and appreciable harm. Total number of events does not meet optimal information size)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Severe intraventricular haemorrhage (grades 3 and 4)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>345 per 1000</P>
</TD>
<TD VALIGN="TOP">
<P>256 per 1000<BR/>(145 to 442)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>RR 0.74<BR/>(0.42 to 1.28)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>118<BR/>(1 RCT)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#9711;&#9711;<BR/>LOW<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Downgraded 2 levels because of:</P>
<P/>
<P>&#8226; serious risk of bias (limitations in trial design (lack of blinding of participants, providers and outcome assessor)</P>
<P/>
<P>&#8226; serious imprecision (95% CI includes both no effect and appreciable harm. Total number of events does not meet OIS)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Chronic lung disease at 36 weeks postmenstrual age (CLD 36 wPMA)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Long-term neurodevelopmental outcomes</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>See comments</P>
</TD>
<TD VALIGN="TOP">
<P>See comments</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on assumed risk in the comparison group and <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>
<B>CI:</B> Confidence interval; <B>OR:</B> Odds ratio; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but it may be substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect of the estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>95% confidence interval includes both no effect and appreciable harm. Total number of events does not meet optimal information size.</P>
<P>
<SUP>b</SUP>Downgraded because of lack of blinding of participants, providers and outcome assessors.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-08-29 20:22:10 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-08-29 20:22:10 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Rescue HFJV vs CV in preterm infants</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.16236252068025714" CI_START="-0.142285300603037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.010038610038610063" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.7895142148749017" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9983264161104328" METHOD="MH" MODIFIED="2015-07-22 08:49:37 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8972250319980809" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="0.12916760111815637">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.16236252068025714" CI_START="-0.142285300603037" EFFECT_SIZE="0.010038610038610063" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-07-22 08:44:46 +1000" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.07771770902075684" STUDY_ID="STD-Keszler-1991" TOTAL_1="74" TOTAL_2="70" VAR="0.0060400422954350295" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9724964291630623" CI_START="0.45434721783887155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.664718772826881" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.012111984652768715" LOG_CI_START="-0.342612126973024" LOG_EFFECT_SIZE="-0.17736205581289638" METHOD="MH" MODIFIED="2015-07-22 08:47:28 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03541166765459025" Q="0.0" RANDOM="NO" SCALE="2.2236218927104936" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="2.103619315724301">
<NAME>Mortality before cross-over</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9724964291630624" CI_START="0.45434721783887155" EFFECT_SIZE="0.664718772826881" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="-0.012111984652768665" LOG_CI_START="-0.342612126973024" LOG_EFFECT_SIZE="-0.17736205581289638" ORDER="301" O_E="0.0" SE="0.1941374196010076" STUDY_ID="STD-Keszler-1991" TOTAL_1="74" TOTAL_2="70" VAR="0.037689337689337694" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0747031278685895" CI_START="0.5449816287586993" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7653061224489796" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.03128851287075611" LOG_CI_START="-0.26361813747234575" LOG_EFFECT_SIZE="-0.11616481230079483" METHOD="MH" MODIFIED="2015-08-29 20:21:53 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.12257040213074147" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="48" WEIGHT="100.0" Z="1.5440740187820523">
<NAME>CLD at 28 to 30 days in survivors</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0747031278685895" CI_START="0.5449816287586993" EFFECT_SIZE="0.7653061224489796" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" LOG_CI_END="0.03128851287075611" LOG_CI_START="-0.26361813747234575" LOG_EFFECT_SIZE="-0.11616481230079483" ORDER="300" O_E="0.0" SE="0.17322962622300078" STUDY_ID="STD-Keszler-1991" TOTAL_1="49" TOTAL_2="48" VAR="0.030008503401360558" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9816396497928507E-31" CI_END="1.2338054252325787" CI_START="0.46415810563408055" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7567567567567567" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="100.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.09124667557191887" LOG_CI_START="-0.33333406102147056" LOG_EFFECT_SIZE="-0.12104369272477582" METHOD="MH" MODIFIED="2015-07-22 09:00:48 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.2637669464456721" Q="0.0" RANDOM="NO" SCALE="2.179580176838078" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="1.1175319926183733">
<NAME>Pulmonary air leak (new)</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2338054252325787" CI_START="0.46415810563408066" EFFECT_SIZE="0.7567567567567568" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.09124667557191887" LOG_CI_START="-0.33333406102147045" LOG_EFFECT_SIZE="-0.12104369272477575" ORDER="302" O_E="0.0" SE="0.24940082638349897" STUDY_ID="STD-Keszler-1991" TOTAL_1="74" TOTAL_2="70" VAR="0.0622007722007722" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2845750002720804" CI_START="0.4207436573201142" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7351712614870509" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.10875946574788355" LOG_CI_START="-0.37598242226036765" LOG_EFFECT_SIZE="-0.13361147825624206" METHOD="MH" MODIFIED="2015-08-29 20:22:10 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.2799345138011017" Q="0.0" RANDOM="NO" SCALE="2.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="55" WEIGHT="100.00000000000001" Z="1.0804664989006827">
<NAME>Severe IVH (grades 3 and 4)</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2845750002720804" CI_START="0.4207436573201142" EFFECT_SIZE="0.7351712614870509" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.10875946574788355" LOG_CI_START="-0.37598242226036765" LOG_EFFECT_SIZE="-0.13361147825624206" ORDER="303" O_E="0.0" SE="0.28473978452709126" STUDY_ID="STD-Keszler-1991" TOTAL_1="63" TOTAL_2="55" VAR="0.08107674489253436" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.063852114424961" CI_START="0.29317630843086034" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.782748601154281" LOG_CI_START="-0.5328711279376813" LOG_EFFECT_SIZE="0.12493873660829993" METHOD="MH" MODIFIED="2008-10-17 01:44:28 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.7097002696402255" Q="0.0" RANDOM="NO" SCALE="6.577323706885011" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="8" WEIGHT="100.0" Z="0.3722586680806563">
<NAME>Necrotising tracheobronchitis at autopsy</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rescue HFJV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours CV</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.06385211442496" CI_START="0.29317630843086046" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.7827486011542809" LOG_CI_START="-0.5328711279376811" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="304" O_E="0.0" SE="0.7728015412913085" STUDY_ID="STD-Keszler-1991" TOTAL_1="9" TOTAL_2="8" VAR="0.5972222222222221" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="33.03366553287184" CI_START="0.4334069347580652" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7837837837837838" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="100.00000000000001" ID="CMP-001.07" LOG_CI_END="1.5189567672237672" LOG_CI_START="-0.36310414400128105" LOG_EFFECT_SIZE="0.5779263116112431" METHOD="MH" MODIFIED="2008-10-17 01:44:36 +1000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.22870705465329721" Q="4.0340186078866304E-32" RANDOM="NO" SCALE="33.80962394237473" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="70" WEIGHT="100.0" Z="1.2036961712772793">
<NAME>Airway obstruction</NAME>
<GROUP_LABEL_1>Rescue HFJV</GROUP_LABEL_1>
<GROUP_LABEL_2>CV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="33.03366553287184" CI_START="0.4334069347580652" EFFECT_SIZE="3.7837837837837838" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.5189567672237672" LOG_CI_START="-0.36310414400128105" LOG_EFFECT_SIZE="0.5779263116112431" ORDER="305" O_E="0.0" SE="1.1055318956053561" STUDY_ID="STD-Keszler-1991" TOTAL_1="74" TOTAL_2="70" VAR="1.2222007722007722" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-06-20 02:15:32 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-06-20 02:15:32 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoIAAALsCAYAAAB3DtY/AABlVklEQVR42uzdf4RX+f///zdrrWSt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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-08-29 20:24:03 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2015-08-29 20:24:03 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2015-07-07 04:04:50 +1000" MODIFIED_BY="[Empty name]">Original search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-29 20:24:03 +1000" MODIFIED_BY="[Empty name]">
<P>Search was made of MEDLINE by means of the MeSH and text words, 'high frequency ventilation', 'high frequency jet ventilation', 'jet ventilation' from the years 1966 to August 2005; EMBASE (1988 to August 2005); and trials register held by the Neonatal Review Group of The Cochrane Collaboration (2005, Issue 3; <I>The Cochrane Library</I>).</P>
<P>In June 2013 and February 2015, we updated the search as follows: MEDLINE (search via PubMed), CINAHL, EMBASE and CENTRAL (<I>The Cochrane Library</I>) were searched from 2005 to 2013, and subsequently from 2013 to 2015. Search string: (high frequency ventilation OR high frequency jet ventilation OR jet ventilation) AND ((infant, newborn[MeSH] OR newborn OR neon* OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh])).</P>
<P>In June 2013, we also searched clinicaltrials.gov and controlled-trials.com for relevant studies.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;# 1 of studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# 1 study included in the previous version of this review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;# 0 of studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# 2 articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# 457 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;# 457 of records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;#470 of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;#19 of additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# 455 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;# 1 of full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;# 1 awaiting for assessment&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>